Naresh Chouhan, Intron Health principal, joins 'Squawk Box' to discuss why he's downgrading Novo Nordisk from buy to sell and slashing the target price. Got a confidential news tip? We want to hear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results